Related Experiment Video

Updated: Dec 30, 2025

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.7K

Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy

Saman Bahrambeigi1, Morteza Molaparast1, Farahnaz Sohrabi2

  • 1Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran.

Immunology Letters
|January 27, 2020
PubMed

Insights

This study explores metabolic reprogramming of T cells to enhance cancer immunotherapy. By overcoming tumor-induced metabolic suppression, therapies like PPAR ligands can improve immune responses and treatment efficacy.

Area of Science:

  • Immunology
  • Oncology
  • Metabolic Engineering

Background:

  • Cancer immunotherapy faces challenges due to tumors creating a tolerant microenvironment.
  • Tumors suppress immune cells metabolically to evade immune detection and destruction.

Purpose of the Study:

  • To investigate metabolic reprogramming of T cells as a strategy to overcome tumor-imposed metabolic restrictions.
  • To identify new therapeutic targets for enhancing cancer immunotherapy.

Main Methods:

  • Examining the role of T cell metabolic reprogramming in cancer immunotherapy.
  • Reviewing studies on the synergistic effects of PPAR ligands in cancer immunotherapy.

Main Results:

  • Metabolic reprogramming of T cells can counteract tumor-induced immune suppression.
  • PPAR ligands show promise in modulating T cell metabolism for improved immunotherapy.

Conclusions:

  • Targeting T cell metabolism offers a novel approach to enhance cancer immunotherapy.
  • Therapeutic agents like PPAR ligands can potentially restore T cell function and improve treatment outcomes by overcoming metabolic restrictions in the tumor microenvironment.
Keywords:
Metabolic reprogrammingPPAR ligandsT cell metabolismTumor microenvironment

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.6K
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

39.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K